The United States spends more on prescription drugs than any other country, and a federal program created more than three decades ago plays a large role in how safety-net providers afford medications. The 340B Drug Pricing Program requires pharmaceutical manufacturers to sell outpatient drugs at steep discounts to eligible healthcare organizations. An important point up front, and one the program’s name and reputation often blur: 340B discounts a provider’s cost of buying drugs – it is not a guarantee that you, as an individual patient, will pay less at the pharmacy counter. Whether any savings reach patients directly is one of the most debated questions in U.S. drug-pricing policy. This article is general information, not legal, medical, or financial advice.
Origins and Purpose of the 340B Drug Pricing Program
Congress established the 340B Drug Pricing Program in 1992 as part of the Veterans Health Care Act. The law, codified in Section 340B of the Public Health Service Act, was designed to help safety-net providers serve low-income and uninsured patients. By requiring manufacturers to offer discounted prices, the program lets these providers “stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services,” in HRSA’s framing. Crucially, the statute directs how entities may buy drugs; it does not, by itself, set what patients pay.
The Health Resources and Services Administration (HRSA), part of the U.S. Department of Health and Human Services, administers the program. Tens of thousands of covered entity sites participate, and discounted 340B purchases have grown into the tens of billions of dollars per year. The program has expanded substantially since its inception, reflecting both broader eligibility over time and rising drug costs.
How 340B Pricing Works
Drug manufacturers that want their products covered by Medicaid must also participate in 340B. They are required to sell covered outpatient drugs to eligible healthcare organizations at or below the 340B “ceiling price.” That ceiling is calculated using a statutory formula based on the Average Manufacturer Price (AMP) minus the Unit Rebate Amount (URA) – the same rebate math used for Medicaid, but applied as a direct discount at the point of purchase rather than as a rebate after the fact.
The resulting discounts vary widely by product; for many drugs they fall roughly in the 25% to 50% range off wholesale acquisition cost, and for some brand-name specialty medications they can be considerably deeper. Treat any specific percentage as a general estimate, not a quote. HRSA calculates and publishes ceiling prices to covered entities through a secure system; these prices are confidential and not publicly disclosed. The gap between the discounted acquisition cost and what the entity is later reimbursed (by insurance or a patient) generates margin – and what happens to that margin is where the patient-benefit question arises.
Eligible Covered Entities
Not every healthcare provider can participate in the 340B Drug Pricing Program. Eligible covered entities include Federally Qualified Health Centers (FQHCs) and FQHC Look-Alikes, Ryan White HIV/AIDS Program grantees, disproportionate share hospitals (DSH hospitals meeting a required adjustment percentage), children’s hospitals, critical access hospitals, sole community hospitals, rural referral centers, free-standing cancer hospitals, and certain specialized clinics (such as hemophilia treatment centers, family planning, tuberculosis, and STD clinics).
Each entity must register with HRSA and comply with program requirements, including maintaining auditable records of 340B purchases and dispensing and avoiding prohibited “duplicate discounts” and drug diversion. Covered entities can operate their own in-house pharmacies or contract with outside retail pharmacies to dispense 340B drugs to eligible patients. For how prescriptions are filled at these pharmacies, see our 340B pharmacy guide.
Who Actually Benefits – and How
This is the part most often misunderstood. The 340B statute requires covered entities to serve their patient populations, but it does not require them to pass drug discounts through to individual patients at the counter, and there is no across-the-board patient-level discount built into the program. In practice, the benefit can reach patients in two very different ways:
Sometimes, directly. Some covered entities – community health centers in particular – operate sliding-fee-scale pharmacies where 340B-priced medications are offered to patients based on ability to pay. In those settings, an uninsured patient might pay far less for a medication than at a retail pharmacy. But this is a policy choice by the entity, not an automatic feature of 340B, and it varies from site to site.
Often, indirectly. When discounts are not passed through at the counter, covered entities generally retain the margin and are expected to reinvest it in patient care – for example, free or reduced-cost primary care, dental and behavioral health services, chronic-disease management, or patient navigation. The benefit to a given patient is then diffuse and hard to see, and critics argue it is hard to verify.
So the honest answer to “does 340B save me money?” is: it can, but not automatically, and not for everyone. If direct out-of-pocket savings are your goal, ask the specific entity how it handles 340B pricing, and also compare other tools such as prescription discount cards, Medicare Extra Help, and State Pharmaceutical Assistance Programs.
340B and Insurance: How They Interact
Patients with insurance, including Medicare Part D and commercial plans, can fill prescriptions through 340B covered entities. When an insured patient fills a prescription at a 340B pharmacy, the plan pays its usual reimbursement, and the covered entity purchases the drug at the 340B price. The difference generates revenue for the entity.
In this common scenario, the patient typically still pays their standard copay or coinsurance – the direct financial benefit goes to the covered entity, not the patient at the point of sale. The indirect benefit (funding for community services) may still matter, but it should not be confused with a personal discount. For patients seeking immediate out-of-pocket savings, the alternatives listed above are often more directly useful.
Growth, Controversy, and the 2024-2025 Disputes
The 340B program has expanded dramatically. The number of participating covered entity sites has grown into the tens of thousands, and by one widely cited estimate, discounted 340B purchases reached roughly $66 billion in 2023 – up sharply from earlier in the decade. That scale has intensified a long-running debate over whether savings are used as Congress intended, and figures are updated periodically, so verify the latest numbers.
Do the savings reach patients? Pharmaceutical manufacturers and some researchers argue the program has grown well beyond its original intent, with large hospital systems generating substantial 340B revenue while not always directing benefits to low-income patients. Analyses (including work published in the New England Journal of Medicine) have questioned whether 340B hospitals consistently provide more charity care than non-340B hospitals. Safety-net providers and patient-advocacy groups counter that the program is essential to funding care in underserved communities and that cutting it would force service reductions.
Contract-pharmacy restrictions. Beginning in 2020, many manufacturers moved to restrict or condition 340B pricing on drugs dispensed through outside contract pharmacies. HRSA pushed back, but federal appellate courts (including the Third and D.C. Circuits) largely sided with manufacturers, holding that Section 340B does not clearly require delivery to an unlimited number of contract pharmacies. Numerous states have since passed “contract pharmacy protection” laws, which are themselves being litigated with mixed results.
The rebate-model debate. More recently, several manufacturers have proposed replacing the up-front discount with a “rebate model,” under which covered entities would pay full price and later receive a rebate after proving a claim was 340B-eligible. Manufacturers say this would curb duplicate discounts and improve program integrity; covered entities warn it would create cash-flow and administrative burdens that shrink the resources funding patient care. HRSA has resisted broad manufacturer-imposed rebate schemes while exploring limited approaches, and the issue was the subject of active litigation and policy debate through 2024-2025. This area is changing quickly – verify the current status before relying on it.
Oversight. Government watchdogs, including the U.S. Government Accountability Office (GAO) and the HHS Office of Inspector General (OIG), have reported gaps in oversight – including how 340B savings are used and how duplicate discounts are prevented – and HRSA has responded over time with additional audits and guidance. Comprehensive reform legislation has repeatedly stalled in Congress.
Navigating the Program as a Patient
If you want to understand whether 340B can help you, start by finding out whether you receive care at a covered entity. HRSA’s Office of Pharmacy Affairs Information System (OPAIS) at HRSA.gov/opa lets you search for registered entities by location. Federally Qualified Health Centers are often the most accessible entry point, as they accept patients regardless of insurance status and typically charge on a sliding scale.
Once you are a patient at a covered entity, ask directly how its pharmacy services work and whether any 340B savings are passed to patients like you – because, as noted, that is an entity-by-entity policy choice rather than a guarantee. Where direct discounts are not available, the services funded by 340B may still benefit you indirectly. You can also combine any available 340B access with manufacturer programs such as those from Novo Nordisk and other savings strategies.
Frequently Asked Questions
Does the 340B program automatically lower my drug prices?
No. 340B discounts what covered entities pay to acquire drugs; it does not automatically reduce your out-of-pocket cost. Some entities (often FQHCs with sliding-fee pharmacies) do pass savings to patients, but many retain the margin to fund services. Ask the specific entity what it does.
Is the 340B Drug Pricing Program the same as Medicaid drug pricing?
No, though the pricing formulas are related. Both use the Average Manufacturer Price and the Medicaid rebate amount, but Medicaid collects rebates after the sale while 340B applies the discount at the point of purchase. The programs are separate, though manufacturers must participate in both.
Can I use 340B if I have commercial insurance?
You can fill prescriptions through 340B covered entities with commercial insurance, but you typically still pay your standard copay or coinsurance. The lower acquisition cost benefits the covered entity, not necessarily you at the counter.
How much can I save with 340B?
It varies widely and is not guaranteed. At some FQHC sliding-fee pharmacies, uninsured patients can save substantially; insured patients often see little or no direct savings and benefit only indirectly. Any specific figures depend on the drug, your coverage, and the entity’s policies – confirm before relying on them.
Does 340B cover specialty drugs?
Yes. The program covers FDA-approved covered outpatient drugs from participating manufacturers, including expensive specialty medications for conditions like cancer, HIV, and hepatitis C. Specialty drugs often carry the largest absolute discounts – but manufacturer contract-pharmacy restrictions may affect where such drugs can be dispensed.
The Bottom Line on 340B
The 340B Drug Pricing Program is a powerful but frequently misunderstood policy tool. It meaningfully lowers what safety-net providers pay for outpatient drugs, and it can – but does not automatically – translate into lower prices or expanded services for patients. Whether you personally benefit depends on the covered entity’s choices and on rules that are actively being contested in the courts and in Congress. Explore the HRSA database to find covered entities near you, ask each one how it handles 340B pricing, and see our healthcare costs guide and healthcare policy guide for additional strategies and context.
Disclaimer: This article is for general informational purposes only and is not legal, medical, financial, or policy advice. The 340B Drug Pricing Program is governed by federal statute and HRSA guidance and is the subject of ongoing litigation and rapidly changing rules on contract pharmacies and rebate models. Discount amounts, eligibility, and whether any savings reach an individual patient vary by covered entity and drug and are not guaranteed. Verify current program details with HRSA and directly with the covered entity, and consult a qualified professional about your specific situation.
Sources
- HRSA Office of Pharmacy Affairs – 340B Drug Pricing Program overview and OPAIS database (hrsa.gov/opa)
- Public Health Service Act, Section 340B; Veterans Health Care Act of 1992
- KFF – 340B Drug Pricing Program explainers, including program-size estimates (approximately $66 billion in 2023) and the rebate-model debate
- U.S. Government Accountability Office (GAO) and HHS Office of Inspector General (OIG) – reports on 340B oversight and program integrity
- Federal appellate litigation on manufacturer contract-pharmacy restrictions (Third Circuit and D.C. Circuit decisions) and related state contract-pharmacy laws